$ORKA

Quoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.

Klein Lawrence Otto (Chief Executive Officer) sold 75,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $91.83 ($90.79–$92.44, $6.89M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards

Oruka Therapeutics Inc. (ORKA) shares have surged over 500% since September 2025, driven by positive clinical trial results for its drug candidates ORKA-001 and ORKA-002. The company announced several key developments, including trial progress, data releases, and a licensing agreement. ORKA's stock reached a 52-week high of $115.52 in August 2026. Investors are watching for upcoming data releases and trial initiations.

Goncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $111.84 ($109.65–$112.56, $0.78M total) across 4 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

Quinlan Paul T (General Counsel) sold 52,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $108.49 ($106.05–$111.14, $5.64M total) across 6 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Agarwal Arjun (Senior Vice President, Finance) sold 10,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $106.66 ($104.67–$108.46, $1.07M total) across 5 trades on 2026-08-13 under a Rule 10b5-1 trading plan.

Oruka Therapeutics (ORKA) reported Q2 2026 net loss of $41.21 million, up from $24.57 million a year earlier. The company said it had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Phase 2 EVERLAST-A 28-week data for ORKA-001 is expected end of Q3 2026, with 52-week data in Dec 2026.

Oruka Therapeutics reported a wider net loss for Q2, citing higher research and development costs. The company’s quarterly results reflect increased spending on R&D, which contributed to the deterioration in profitability. The update is relevant for investors tracking Oruka’s burn rate and funding needs.